cVAD (USPella)

Assess the safety of the technology and develop best practice guidelines for clinical course of patients requiring Impella 2.5, Impella 5.0/LD or Impella CP support.

August 09, 2017

  • Clinical Trial Information

    Trial Contact: Tinetti, Meghan

    Trial Phone: 321.841.3682

  • Age Group: Adult

    Phase: Not applicable

    Principal Investigator: Vijaykumar S Kasi, MD

    Sub Investigators: N/A

    IRB No: 11.097.10

    Secondary Protocol No:

    Applicable Disease Sites: Heart Failure